中樞神經系統（CNS）生物標記：科技與全球市場

全球中樞神經系統 (CNS) 生物標記市場預計將從 2025 年的 76 億美元成長到 2030 年底的 138 億美元，2025 年至 2030 年的複合年成長率為 12.6%。

預計北美市場將從 2025 年的 27 億美元成長到 2030 年底的 50 億美元，2025 年至 2030 年的複合年成長率為 13.4%。

預計亞太市場將從 2025 年的 17 億美元成長到 2030 年底的 32 億美元，2025 年至 2030 年的複合年成長率為 14.1%。

本報告考察了全球中樞神經系統 (CNS) 生物標記市場，並提供了市場概況、市場影響因素和市場機會分析、技術趨勢、法律制度、市場規模趨勢和預測、按各個細分市場和地區進行的詳細分析以及主要企業的概況。

目錄

第1章執行摘要

• 市場展望
• 調查範圍
• 市場概況
• 市場動態與成長要素
• 新興技術
• 細分市場分析
• 區域分析
• 結論

第2章 市場概覽

• 當前市場概況
• 前景
• 宏觀經濟因素分析
• 美國關稅對市場的影響
• 烏克蘭-俄羅斯戰爭的影響
• 全球經濟穩定與供應鏈
• 公共和私人研發投資
• 醫療費用支出和經濟成長
• 老化和疾病負擔
• 波特五力分析

第3章 市場動態

• 市場動態概覽
• 市場促進因素
• 神經系統疾病的盛行率
• 診斷技術和研究的進展
• 重點關注早期檢測和個人化醫療
• 市場限制
• 先進診斷測試高成本
• 監管和檢驗的挑戰
• 醫療保健提供者對此認知不足且接受度不高
• 市場機遇
• 神經退化性疾病研究的進展
• 擴大早期診斷和篩檢計劃
• 與個人化醫療結合

第4章：監理現狀

• 法律規範
• 美國
• 歐洲
• 印度
• 澳洲
• 日本

第5章 新興技術與專利分析

• 概述
• 新興技術
• 高解析度質譜
• 次世代定序
• 多重免疫檢測
• 單細胞RNA定序
• 專利分析
• 重點總結
• 專利：按年份
• 專利：按主要司法管轄區分類
• 專利：由申請人

第6章 市場區隔分析

• 細分市場分析
• 全球中樞神經系統生物標記市場（依疾病分類）
• 重點總結
• 阿茲海默症
• 多發性硬化症、肌萎縮側索硬化症、額顳葉失智症
• 帕金森氏症
• 其他
• 全球中樞神經系統生物標記市場按應用領域分類
• 重點總結
• 藥物發現與開發
• 臨床診斷
• 個人化醫療
• 全球中樞神經系統生物標記市場（按技術分類）
• 重點總結
• 蛋白質體學
• 分子影像
• 基因組學
• 全球中樞神經系統生物標記市場（按生物標記類型分類）
• 重點總結
• BETA-澱粉樣蛋白
• Tau蛋白
• 其他
• 地理細分
• 全球中樞神經系統生物標記市場（按地區分類）
• 重點總結
• 北美洲
• 歐洲
• 亞太地區
• 中東和非洲
• 南美洲

第7章 競爭訊息

• 產業結構
• 公司市佔率分析
• 戰略分析

8. 中樞神經系統（CNS）生物標記市場的永續性：ESG視角

• ESG簡介
• 中樞神經系統生物標記產業的永續性趨勢和舉措
• 結論

第9章附錄

• 調查方法
• 簡稱
• 公司簡介
• ABBOTT
• BIOMERIEUX
• BIO-RAD LABORATORIES INC.
• C2N DIAGNOSTICS
• F. HOFFMANN-LA ROCHE LTD.
• FUJIREBIO
• LABCORP
• LILLY USA LLC.
• MERCK KGAA
• QUANTERIX
• QUEST DIAGNOSTICS INC.
• REVVITY
• SIEMENS HEALTHINEERS AG
• SYSMEX CORP.
• THERMO FISHER SCIENTIFIC INC.
• 新興Start-Ups和市場顛覆者

The global market for central nervous system (CNS) biomarkers is estimated to grow from $7.6 billion in 2025 to reach $13.8 billion by the end of 2030, at a compound annual growth rate (CAGR) of 12.6% from 2025 through 2030.

The North American market for CNS biomarkers is estimated to grow from $2.7 billion in 2025 to reach $5 billion by the end of 2030, at a CAGR of 13.4% from 2025 through 2030.

The Asia-Pacific market for CNS biomarkers is estimated to grow from $1.7 billion in 2025 to reach $3.2 billion by the end of 2030, at a CAGR of 14.1% from 2025 through 2030.

Report Scope

The report examines and segments the global central nervous system (CNS) biomarkers market by disease, application, technology and biomarker type. It also provides insights into emerging trends and potential growth drivers. The report focuses on Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis, frontotemporal dementia, Parkinson's disease and others. By application, it examines drug discovery and development, clinical diagnostics and personalized medicine. By technology, proteomics, molecular imaging and genomics are reviewed. Finally, biomarker types such as amyloid-beta, tau protein and others are considered.

The report also provides an inclusive regional analysis covering North America, Europe, Asia-Pacific, South America and the Middle East and Africa. It evaluates the impact of AI adoption on the CNS biomarkers industry and market dynamics, including drivers, challenges and emerging trends, while highlighting innovations in product and performance enhancements. The study concludes with an analysis of major market participants and their offerings.

Global revenue ($ million) for the base year of 2024, estimates for 2025 and data for the forecast period 2025 through 2030 are also part of the report.

Report Includes

• 141 data tables and 44 additional tables
• An up-to-date overview and analysis of the global market for central nervous system (CNS) biomarkers
• In-depth analysis of global market trends, featuring historical revenue data for 2022-2024, estimated figures for 2025, as well as forecasts for 2030, including projections of CAGRs through 2030
• Analysis of market opportunities with a holistic review of Porter's Five Forces model and industry supply chain analysis, considering both micro- and macro-environmental factors prevailing in the market
• Explanation of market drivers, restraints and other forces impacting the global market
• Discussion of CNS disease segments, prevalence and gaps in treatment for Alzheimer's disease, depression, Parkinson's disease, multiple sclerosis, etc.
• Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the practices of leading companies
• Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
• Profiles of the leading global companies, including Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers, Abbott and Bio-Rad Laboratories Inc.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Current Market Overview
• Outlook
• Analysis of Macroeconomic Factors
• Impact of U.S. Tariffs on the Market
• Impact of the Ukraine-Russia War
• Global Economic Stability and Supply Chains
• Public and Private R&D Investment
• Healthcare Expenditure and Economic Growth
• Aging Population and Disease Burden
• Porter's Five Forces Analysis
• Bargaining Power of Buyers: Moderate to High
• Bargaining Power of Suppliers: High
• Potential for New Entrants: Moderate to Low
• Threat of Substitute: Moderate
• Competition in the Industry: High

Chapter 3 Market Dynamics

• Market Dynamics Snapshot
• Market Drivers
• Prevalence of Neurological Disorders
• Advances in Diagnostic Technologies and Research
• Focus on Early Detection and Personalized Medicine
• Market Restraints
• High Cost of Advanced Diagnostic Assays
• Regulatory and Validation Challenges
• Limited Awareness and Adoption Among Healthcare Providers
• Market Opportunities
• Growth in Neurodegenerative Disease Research
• Expansion of Early Diagnosis and Screening Programs
• Integration with Personalized Medicine

Chapter 4 Regulatory Landscape

• Regulatory Framework
• U.S.
• Europe
• India
• Australia
• Japan

Chapter 5 Emerging Technologies and Patent Analysis

• Overview
• Emerging Technologies
• High-Resolution Mass Spectrometry
• Next-Generation Sequencing
• Multiplexed Immunoassays
• Single-Cell RNA Sequencing
• Patent Analysis
• Key Takeaways
• Patents by Year
• Patents by Leading Jurisdiction
• Patents by Applicants

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global CNS Biomarkers Market, by Disease
• Key Takeaways
• Alzheimer's Disease
• MS, ALS and FTD
• Parkinson's Disease
• Others
• Global CNS Biomarkers Market, by Application
• Key Takeaways
• Drug Discovery and Development
• Clinical Diagnostics
• Personalized Medicine
• Global CNS Biomarkers Market, by Technology
• Key Takeaways
• Proteomics
• Molecular Imaging
• Genomics
• Global CNS Biomarkers Market, by Biomarker Type
• Key Takeaways
• Amyloid-Beta
• Tau Protein
• Others
• Geographic Breakdown
• Global CNS Biomarkers Market, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• South America

Chapter 7 Competitive Intelligence

• Industry Structure
• Company Market Share Analysis
• Strategic Analysis

Chapter 8 Sustainability in the CNS Biomarkers Market: An ESG Perspective

• Introduction to ESG
• Sustainability Trends and Initiatives in the CNS Biomarkers Industry
• Concluding Remarks

Chapter 9 Appendix

• Methodology
• Abbreviations
• Company Profiles
• ABBOTT
• BIOMERIEUX
• BIO-RAD LABORATORIES INC.
• C2N DIAGNOSTICS
• F. HOFFMANN-LA ROCHE LTD.
• FUJIREBIO
• LABCORP
• LILLY USA LLC.
• MERCK KGAA
• QUANTERIX
• QUEST DIAGNOSTICS INC.
• REVVITY
• SIEMENS HEALTHINEERS AG
• SYSMEX CORP.
• THERMO FISHER SCIENTIFIC INC.
• Emerging Start-ups/Market Disruptors

List of Tables

• Summary Table : Global Market for CNS Biomarkers, by Region, Through 2030
• Table 1 : Patents Granted for CNS Biomarkers, by Year, 2022-2025
• Table 2 : Patents Granted for CNS Biomarkers, by Top Jurisdiction, 2022-2025
• Table 3 : Patents Granted for CNS Biomarkers, by Applicants, 2022-2025
• Table 4 : Global Market for CNS Biomarkers, by Disease, Through 2030
• Table 5 : Global Market for Alzheimer's Disease in CNS Biomarkers, by Region, Through 2030
• Table 6 : Global Market for MS, ALS and FTD in CNS Biomarkers, by Region, Through 2030
• Table 7 : Global Market for Parkinson's Disease in CNS Biomarkers, by Region, Through 2030
• Table 8 : Global Market for Other Diseases in CNS Biomarkers, by Region, Through 2030
• Table 9 : Global Market for CNS Biomarkers, by Application, Through 2030
• Table 10 : Global Market for CNS Biomarkers for Drug Discovery and Development, by Region, Through 2030
• Table 11 : Global Market for CNS Biomarkers for Clinical Diagnostics, by Region, Through 2030
• Table 12 : Global Market for CNS Biomarkers for Personalized Medicine, by Region, Through 2030
• Table 13 : Global Market for CNS Biomarkers, by Technology, Through 2030
• Table 14 : Global Market for Proteomic Biomarkers, by Region, Through 2030
• Table 15 : Global Market for Molecular Imaging in CNS Biomarkers, by Region, Through 2030
• Table 16 : Global Market for Genomic Biomarkers, by Region, Through 2030
• Table 17 : Global Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 18 : Global Market for Amyloid-Beta Biomarkers, by Region, Through 2030
• Table 19 : Global Market for Tau Protein Biomarkers, by Region, Through 2030
• Table 20 : Global Market for Other CNS Biomarkers, by Region, Through 2030
• Table 21 : Global Market for CNS Biomarkers, by Region, Through 2030
• Table 22 : North American Market for CNS Biomarkers, by Disease, Through 2030
• Table 23 : North American Market for CNS Biomarkers, by Application, Through 2030
• Table 24 : North American Market for CNS Biomarkers, by Technology, Through 2030
• Table 25 : North American Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 26 : North American Market for CNS Biomarkers, by Country, Through 2030
• Table 27 : U.S. Market for CNS Biomarkers, by Disease, Through 2030
• Table 28 : U.S. Market for CNS Biomarkers, by Application, Through 2030
• Table 29 : U.S. Market for CNS Biomarkers, by Technology, Through 2030
• Table 30 : U.S. Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 31 : Canadian Market for CNS Biomarkers, by Disease, Through 2030
• Table 32 : Canadian Market for CNS Biomarkers, by Application, Through 2030
• Table 33 : Canadian Market for CNS Biomarkers, by Technology, Through 2030
• Table 34 : Canadian Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 35 : Mexican Market for CNS Biomarkers, by Disease, Through 2030
• Table 36 : Mexican Market for CNS Biomarkers, by Application, Through 2030
• Table 37 : Mexican Market for CNS Biomarkers, by Technology, Through 2030
• Table 38 : Mexican Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 39 : Prevalence of Dementia in Europe, by Age Group and Sex, 2025
• Table 40 : European Market for CNS Biomarkers, by Disease, Through 2030
• Table 41 : European Market for CNS Biomarkers, by Application, Through 2030
• Table 42 : European Market for CNS Biomarkers, by Technology, Through 2030
• Table 43 : European Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 44 : European Market for CNS Biomarkers, by Country, Through 2030
• Table 45 : German Market for CNS Biomarkers, by Disease, Through 2030
• Table 46 : German Market for CNS Biomarkers, by Application, Through 2030
• Table 47 : German Market for CNS Biomarkers, by Technology, Through 2030
• Table 48 : German Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 49 : U.K. Market for CNS Biomarkers, by Disease, Through 2030
• Table 50 : U.K. Market for CNS Biomarkers, by Application, Through 2030
• Table 51 : U.K. Market for CNS Biomarkers, by Technology, Through 2030
• Table 52 : U.K. Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 53 : French Market for CNS Biomarkers, by Disease, Through 2030
• Table 54 : French Market for CNS Biomarkers, by Application, Through 2030
• Table 55 : French Market for CNS Biomarkers, by Technology, Through 2030
• Table 56 : French Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 57 : Italian Market for CNS Biomarkers, by Disease, Through 2030
• Table 58 : Italian Market for CNS Biomarkers, by Application, Through 2030
• Table 59 : Italian Market for CNS Biomarkers, by Technology, Through 2030
• Table 60 : Italian Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 61 : Spanish Market for CNS Biomarkers, by Disease, Through 2030
• Table 62 : Spanish Market for CNS Biomarkers, by Application, Through 2030
• Table 63 : Spanish Market for CNS Biomarkers, by Technology, Through 2030
• Table 64 : Spanish Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 65 : Rest of Europe Market for CNS Biomarkers, by Disease, Through 2030
• Table 66 : Rest of Europe Market for CNS Biomarkers, by Application, Through 2030
• Table 67 : Rest of Europe Market for CNS Biomarkers, by Technology, Through 2030
• Table 68 : Rest of Europe Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 69 : Asia-Pacific Market for CNS Biomarkers, by Disease, Through 2030
• Table 70 : Asia-Pacific Market for CNS Biomarkers, by Application, Through 2030
• Table 71 : Asia-Pacific Market for CNS Biomarkers, by Technology, Through 2030
• Table 72 : Asia-Pacific Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 73 : Asia-Pacific Market for CNS Biomarkers, by Country, Through 2030
• Table 74 : Chinese Market for CNS Biomarkers, by Disease, Through 2030
• Table 75 : Chinese Market for CNS Biomarkers, by Application, Through 2030
• Table 76 : Chinese Market for CNS Biomarkers, by Technology, Through 2030
• Table 77 : Chinese Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 78 : Japanese Market for CNS Biomarkers, by Disease, Through 2030
• Table 79 : Japanese Market for CNS Biomarkers, by Application, Through 2030
• Table 80 : Japanese Market for CNS Biomarkers, by Technology, Through 2030
• Table 81 : Japanese Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 82 : Indian Market for CNS Biomarkers, by Disease, Through 2030
• Table 83 : Indian Market for CNS Biomarkers, by Application, Through 2030
• Table 84 : Indian Market for CNS Biomarkers, by Technology, Through 2030
• Table 85 : Indian Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 86 : South Korean Market for CNS Biomarkers, by Disease, Through 2030
• Table 87 : South Korean Market for CNS Biomarkers, by Application, Through 2030
• Table 88 : South Korean Market for CNS Biomarkers, by Technology, Through 2030
• Table 89 : South Korean Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 90 : Australian Market for CNS Biomarkers, by Disease, Through 2030
• Table 91 : Australian Market for CNS Biomarkers, by Application, Through 2030
• Table 92 : Australian Market for CNS Biomarkers, by Technology, Through 2030
• Table 93 : Australian Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 94 : Rest of Asia-Pacific Market for CNS Biomarkers, by Disease, Through 2030
• Table 95 : Rest of Asia-Pacific Market for CNS Biomarkers, by Application, Through 2030
• Table 96 : Rest of Asia-Pacific Market for CNS Biomarkers, by Technology, Through 2030
• Table 97 : Rest of Asia-Pacific Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 98 : MEA Market for CNS Biomarkers, by Disease, Through 2030
• Table 99 : MEA Market for CNS Biomarkers, by Application, Through 2030
• Table 100 : MEA Market for CNS Biomarkers, by Technology, Through 2030
• Table 101 : MEA Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 102 : MEA Market for CNS Biomarkers, by Country, Through 2030
• Table 103 : Middle East Market for CNS Biomarkers, by Disease, Through 2030
• Table 104 : Middle East Market for CNS Biomarkers, by Application, Through 2030
• Table 105 : Middle East Market for CNS Biomarkers, by Technology, Through 2030
• Table 106 : Middle East Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 107 : African Market for CNS Biomarkers, by Disease, Through 2030
• Table 108 : African Market for CNS Biomarkers, by Application, Through 2030
• Table 109 : African Market for CNS Biomarkers, by Technology, Through 2030
• Table 110 : African Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 111 : South American Market for CNS Biomarkers, by Disease, Through 2030
• Table 112 : South American Market for CNS Biomarkers, by Application, Through 2030
• Table 113 : South American Market for CNS Biomarkers, by Technology, Through 2030
• Table 114 : South American Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 115 : South American Market for CNS Biomarkers, by Country, Through 2030
• Table 116 : Brazilian Market for CNS Biomarkers, by Disease, Through 2030
• Table 117 : Brazilian Market for CNS Biomarkers, by Application, Through 2030
• Table 118 : Brazilian Market for CNS Biomarkers, by Technology, Through 2030
• Table 119 : Brazilian Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 120 : Argentine Market for CNS Biomarkers, by Disease, Through 2030
• Table 121 : Argentine Market for CNS Biomarkers, by Application, Through 2030
• Table 122 : Argentine Market for CNS Biomarkers, by Technology, Through 2030
• Table 123 : Argentine Market for CNS Biomarkers, by Biomarker Type, Through 2030
• Table 124 : Rest of South America Market for CNS Biomarkers, by Disease, Through 2030
• Table 125 : Rest of South America Market for CNS Biomarkers, by Application, Through 2030
• Table 126 : Rest of South America Market for CNS Biomarkers, by Technology, Through 2030
• Table 127 : Rest of South America Market for CNS Biomarkers, by Biomarker Type,Through 2030
• Table 128 : Strategic Initiatives for CNS Biomarkers Market, 2024 and 2025
• Table 129 : Abbreviations Used in the Global CNS Biomarkers Market Report
• Table 130 : Abbott: Company Snapshot
• Table 131 : Abbott: Financial Performance, FY 2023 and 2024
• Table 132 : Abbott: Product Portfolio
• Table 133 : Abbott: News/Key Developments, 2023 and 2024
• Table 134 : bioMerieux: Company Snapshot
• Table 135 : bioMerieux: Financial Performance, FY 2023 and 2024
• Table 136 : bioMerieux: Product Portfolio
• Table 137 : bioMerieux: News/Key Developments, 2023 and 2024
• Table 138 : Bio-Rad Laboratories Inc.: Company Snapshot
• Table 139 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2023 and 2024
• Table 140 : Bio-Rad Laboratories Inc.: Product Portfolio
• Table 141 : Bio-Rad Laboratories Inc.: News/Key Developments, 2024 and 2025
• Table 142 : C2N Diagnostics: Company Snapshot
• Table 143 : C2N Diagnostics: Product Portfolio
• Table 144 : C2N Diagnostics: News/Key Developments, 2022-2025
• Table 145 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 146 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 147 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 148 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023
• Table 149 : Fujirebio: Company Snapshot
• Table 150 : Fujirebio: Product Portfolio
• Table 151 : Fujirebio: News/Key Developments, 2023-2025
• Table 152 : Labcorp: Company Snapshot
• Table 153 : Labcorp: Financial Performance, FY 2023 and 2024
• Table 154 : Labcorp: Product Portfolio
• Table 155 : Labcorp: News/Key Developments, 2024 and 2025
• Table 156 : Lilly USA LLC.: Company Snapshot
• Table 157 : Lilly USA LLC.: Financial Performance, FY 2023 and 2024
• Table 158 : Lilly USA LLC.: Product Portfolio
• Table 159 : Merck KGaA: Company Snapshot
• Table 160 : Merck KGaA: Financial Performance, FY 2023 and 2024
• Table 161 : Merck KGaA: Product Portfolio
• Table 162 : Merck KGaA: News/Key Developments, 2024
• Table 163 : Quanterix: Company Snapshot
• Table 164 : Quanterix: Financial Performance, FY 2023 and 2024
• Table 165 : Quanterix: Product Portfolio
• Table 166 : Quanterix: News/Key Developments, 2025
• Table 167 : Quest Diagnostics Inc.: Company Snapshot
• Table 168 : Quest Diagnostics Inc.: Financial Performance, FY 2023 and 2024
• Table 169 : Quest Diagnostics Inc.: Product Portfolio
• Table 170 : Revvity: Company Snapshot
• Table 171 : Revvity: Financial Performance, FY 2023 and 2024
• Table 172 : Revvity: Product Portfolio
• Table 173 : Siemens Healthineers AG: Company Snapshot
• Table 174 : Siemens Healthineers AG: Financial Performance, FY 2023 and 2024
• Table 175 : Siemens Healthineers AG: Product Portfolio
• Table 176 : Siemens Healthineers AG: News/Key Developments, 2024 and 2025
• Table 177 : Sysmex Corp.: Company Snapshot
• Table 178 : Sysmex Corp.: Financial Performance, FY 2023 and 2024
• Table 179 : Sysmex Corp.: Product Portfolio
• Table 180 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 181 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
• Table 182 : Thermo Fisher Scientific Inc.: Product Portfolio
• Table 183 : Thermo Fisher Scientific Inc.: News/Key Developments, 2025
• Table 184 : List of a Few Emerging Startups

List of Figures

• Summary Figure : Global Market Share for CNS Biomarkers, by Region, 2024
• Figure 1 : Porter's Five Forces Analysis: CNS Biomarkers Market
• Figure 2 : Market Dynamics of CNS Biomarkers
• Figure 3 : Global Market Share for CNS Biomarkers, by Disease, 2024
• Figure 4 : Global Market Share for Alzheimer's Disease in CNS Biomarkers, by Region, 2024
• Figure 5 : Global Market Share for MS, ALS and FTD in CNS Biomarkers, by Region, 2024
• Figure 6 : Global Market Share for Parkinson's Disease in CNS Biomarkers, by Region, 2024
• Figure 7 : Global Market Share for Other Diseases in CNS Biomarkers, by Region, 2024
• Figure 8 : Global Market Share for CNS Biomarkers, by Application, 2024
• Figure 9 : Global Market Share for CNS Biomarkers for Drug Discovery and Development, by Region, 2024
• Figure 10 : Global Market Share for CNS Biomarkers for Clinical Diagnostics, by Region, 2024
• Figure 11 : Global Market Share for CNS Biomarkers for Personalized Medicine, by Region, 2024
• Figure 12 : Global Market Share for CNS Biomarkers, by Technology, 2024
• Figure 13 : Global Market Share for Proteomic Biomarkers, by Region, 2024
• Figure 14 : Global Market Share for Molecular Imaging in CNS Biomarkers, by Region, 2024
• Figure 15 : Global Market Share for Genomic Biomarkers, by Region, 2024
• Figure 16 : Global Market Share for CNS Biomarkers, by Biomarker Type, 2024
• Figure 17 : Global Market Share for Amyloid-beta Biomarkers, by Region, 2024
• Figure 18 : Global Market Share for Tau Protein Biomarkers, by Region, 2024
• Figure 19 : Global Market Share for Other CNS Biomarkers, by Region, 2024
• Figure 20 : Global Market Share for CNS Biomarkers, by Region, 2024
• Figure 21 : North American Market Share for CNS Biomarkers, by Country, 2024
• Figure 22 : European Market Share for CNS Biomarkers, by Country, 2024
• Figure 23 : Asia-Pacific Market Share for CNS Biomarkers, by Country, 2024
• Figure 24 : MEA Market Share for CNS Biomarkers, by Country, 2024
• Figure 25 : South American Market Share for CNS Biomarkers, by Country, 2024
• Figure 26 : Global Market Share for CNS Biomarkers, by Leading Companies, FY 2024
• Figure 27 : Abbott: Revenue Share, by Business Unit, FY 2024
• Figure 28 : Abbott: Revenue Share, by Country/Region, FY 2024
• Figure 29 : bioMerieux: Revenue Share, by Business Unit, FY 2024
• Figure 30 : bioMerieux: Revenue Share, by Country/Region, FY 2024
• Figure 31 : Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 32 : Bio-Rad Laboratories Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 33 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
• Figure 34 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
• Figure 35 : Labcorp: Revenue Share, by Business Unit, FY 2024
• Figure 36 : Labcorp: Revenue Share, by Country/Region, FY 2024
• Figure 37 : Lilly USA LLC.: Revenue Share, by Country/Region, FY 2024
• Figure 38 : Merck KGaA: Revenue Share, by Business Unit, FY 2024
• Figure 39 : Merck KGaA: Revenue Share, by Country/Region, FY 2024
• Figure 40 : Quanterix: Revenue Share, by Business Unit, FY 2024
• Figure 41 : Quanterix: Revenue Share, by Country/Region, FY 2024
• Figure 42 : Quest Diagnostics Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 43 : Revvity: Revenue Share, by Business Unit, FY 2024
• Figure 44 : Revvity: Revenue Share, by Country/Region, FY 2024
• Figure 45 : Siemens Healthineers AG: Revenue Share, by Business Unit, FY 2024
• Figure 46 : Siemens Healthineers AG: Revenue Share, by Country/Region, FY 2024
• Figure 47 : Sysmex Corp.: Revenue Share, by Country/Region, FY 2024
• Figure 48 : Thermo Fisher Scientific Inc.: Revenue Share, by Business Unit, 2024
• Figure 49 : Thermo Fisher Scientific Inc.: Revenue Share, by Country/Region, 2024